U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473973) titled 'ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency' on March 11.
Brief Summary: The primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.
Study Start Date: March 26, 2025
Study Type: INTERVENTIONAL
Condition:
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Autosomal Recessive Hypophosphatemic Rickets
Generalized Arterial Calcification of Infancy 1
Intervention:
DRUG: INZ-701
Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunog...